Published: 21 December 2023
Author(s): Mathias Chéa, Chloé Bourguignon, Sylvie Bouvier, Eva Nouvellon, Jeremy Laurent, Antonia Perez-Martin, Eve Mousty, Sylvie Ripart, Mariya Gennadevna Nikolaeva, Jamilya Khizroeva, Victoria Bitsadze, Alexander Makatsariya, Jean-Christophe Gris
Issue: May 2024
Section: Original Article

Venous thromboembolism (VTE), deep vein thrombosis (DVT) and/or pulmonary embolism (PE) is a rare event in women of childbearing age, affecting 2–10/10,000 persons per year [1]. Exogenous sex steroids, mainly combined oral contraceptives (COCs) containing both synthetic oestrogen and progestogen, are slight transient risk factors for VTE [2]. They remain with pregnancy the most common risk factors in women of childbearing age [3]. Women who have their first VTE whilst taking oestrogens have a slight risk of recurrent VTE after stopping anticoagulation [4,5] and might not globally benefit from extended anticoagulant therapy.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.